PTU - Polskie Towarzystwo Urologiczne
list of articles:

Evaluation of some cell reactivity parameters in peripheral blood mononuclear cells of patients with prostate adenocarcinoma
Article published in Urologia Polska 2005/58/3.

authors

Anna Helmin-Basa 1, Lidia Gackowska 1, Małgorzata Wyszomirska-Gołda 1, Marcin Sawicki 3, Ryszard Gołda 1, Izabela Kubiszewska 1, Jacek Michałkiewicz 1, Zbigniew Wolski 2, Aleksander Łapuć 2
1 Uniwersytet Mikołaja Kopernika w Toruniu, Katedra i Zakład Immunologii Collegium Medicum w Bydgoszczy
Kierownik katedry i zakładu: dr hab. prof. UMK Jacek Michałkiewicz
2 Uniwersytet Mikołaja Kopernika w Toruniu, Katedra i Klinika Urologii Collegium Medicum w Bydgoszczy
Kierownik katedry i zakładu: prof. dr hab. Zbigniew Wolski
3 Uniwersytet Mikołaja Kopernika w Toruniu, Katedra i Zakład Diagnostyki Laboratoryjnej Collegium Medicum w Bydgoszczy
Kierownik katedry i zakładu: prof. dr hab. Grażyna Odrowąż-Sypniewska

keywords

prostate, prostate adenocarcinoma, cytokines, lymphocytes, monocytes, proliferative response, peripheral blood mononuclear cells

summary

Introduction.
Activation of T lymphocytes plays important role in anticancer response. Patients with cancer have a dysfunction of cellular immunological response.
The aim of the study.
The purpose of the study is to evaluate:
1) anti-CD3 antibody induced peripheral blood mononuclear cells (PBMC) proliferative response in patients with prostate adenocarcinoma;
2) profile of cytokine synthesis by PBMC after induction of anti-CD3 antibodies in prostate adenocarcinoma patients.
Material and methods.
The study material were peripheral blood mononuclear cells (PBMC) obtained from patients with prostate adenocarcinoma and healthy donors. 3H thymidine incorporation was used as an estimate for PBMC proliferative response after anti-CD3 antibodies stimulation. Cytokine concentration in PBMC culture supernatants (IFN-g, TNF-a, IL-10, IL-12 and IL-6) in response to induction of anti-CD3 antibodies or medium alone was determined using ELISA in both patients with prostate adenocarcinoma and control group.
Results.
There was low PBMC proliferative response after stimulation of anti-CD3 antibodies in patients with prostate adenocarcinoma. The concentration of IFN-g was decreased but the amount of TNF-a did not differ between study group of patients and controls. The level of IL-12 was higher in patients with prostate adenocarcinoma than controls but the difference did not reach the level of significance. In case of Th2 type cytokines such as IL-10 but not IL-6 there were no differences between patients with prostate adenocarcinoma and controls. The study showed that patients with prostate cancer response with spontaneous increase in IL-6 synthesis.
Conclusions.
The results of these studies demonstrate Th1/Th2 unbalance in patients with prostate adenocarcinoma. Such changed cellular response depending on Th1 lymphocytes may accelerate the cancer progression. The detection of prolifertive activity and levels of monocines and lymphocines producing by peripheral blood mononuclear cells may reflect anticancer condition of immunological system activity.

references

  1. Lutz W, Tarkowski M: Układ odpornościowy w chorobach nowotworowych; w Lutz W, Tarkowski M: Znaczenie i diagnostyka układu odpornościowego w chorobach nowotworowych. Łódź, IMP im. prof. J. Nofera, 2001, str. 48-85
  2. Pawelec G: Tumor escape from the immune response. Cancer Immunol Immunother 2004; 53; 843
  3. Yang L, Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004; 92; 13-27.
  4. Piemonti L, Zerbi A, Di Carlo V: Strategies for tumor immune escape. Drugs Today (Barc); 2003; 39; 701-724.
  5. Gabrilovich D, Pisarev V: Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003; 4: 525-536.
  6. Bander MH, Yao D, Liu H et al: MHC class I and MHC class II expression in prostate cancer and modulation by interferon-alfa and gamma. Prostate 2000; 33; 1997-1999.
  7. Kavanaugh DY, Carbone DP: Immunologic dysfunction in cancer. Hematology/oncology clinics of North America 1996; 20; 927-949.
  8. Łącki JK, Wiktorowicz KE: Biologiczne właściwości interleukiny 10. Post Hig Med Dośw 1994; 48; 363-370.
  9. Yu L, Wu Y, Hui Y et al Expression of IL-4 and IL-10 by PBMC and tumor tissue in cancer patients. Zhogguo Yi Xoe Ke Xue Yuan Xue Bao 1997; 19; 227-231.
  10. Shurin GV, Aalamian M, Pirtshalaishvili G et al: Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoetic progrenitors. Eur Urol 2001; 39; 37-40.
  11. Aalamian M, Tourkova IL, Chatta GS et al: Inhibition of dendropoesis by tumor derived and purified prostate specific antigen. Urol 2003; 170; 2026-2030.
  12. Oh BR, Sasaki M, Perinchery G et al: Frequent genotype changes at 308 and 488 regions of tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 2000; 163; 1584-1587.
  13. Kennedy-Smith AG, McKenzie JL, Owen MC et al: Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 2002; 168; 741-747.
  14. Romagnani S: Biology of human TH1 and TH2 cells. J Clin Immunol 1995 May; 15; 121-129.
  15. Picker LJ, Singh MK et al: Direct demonstration of cytokine synthesis heterogeneity among human memory/effectory T cells by flow cytometry. Blood 1995; 86; 1408-1419.
  16. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996; 383; 787-793.
  17. Romagnani S, Parronchi P, D?Elios MM et al: An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997; 113; 153-156.
  18. Oriss TB, McCarthy SA, Morel BF et al: Crossregulation between T helper cell (Th) 1 and Th2: inhibition of Th2 proliferation by IFN-gamma involves interference with IL-1. J Immunol 1997; 15; 158 (8); 3666-3672.
  19. Steffen J: Interleukiny i ich receptory w nowotworach u ludzi: synteza, uwalnianie, występowanie w surowicy krwi. Diag Lab 1994; 30; 221-240.
  20. Sato M, Goto S, Kaneko R et al: Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 1998; 18: 3951-3955.
  21. Elsasser-Beile U, Kolble N Grussenmeyer T et al: Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Biol 1998, 19; 470-476.
  22. Kamińska J, Kowalska M, Rysińska A et al: Cytokiny w surowicy krwi u chorych na nowotwory złośliwe. Nowotwory 1999; 49; 21-25.
  23. Morris MJ, Scher HI: Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000; 89: 1329-1348.
  24. Michałkiewicz J, Stachowski J, Barth C et al: Effect of Pseudomonas aeruginosa exotoxin A on IFN-g synthesis: expression of costimulatory molecules on monocytes and activity of NK cell. Immunolo Lett 1999; 69; 359-366.
  25. Socha P, Michałkiewicz J, Stachowski J et al: Deficiency of the expression of CD45RA isoform of CD45 common leucocyte antigen in CD4+ T lymphocytes in children with infantile cholestasis. Immunolo Lett 2001; 75; 179-184.
  26. Filell X, Alcover J, Zarco MA et al: Analysis of type Th1 and Th2 cytokines in patients with prostate cancer. Prostate 2000; 44; 271-274.
  27. Shigenori G, Manami S, Ryuta K et al: Analysis of Th1 and Th2 cytokine production by peripheral blood mononuc1ear cell s as a parameter of immunological dysfuncion in advanced cancer patient. Cancer Immunol Immunother 1999; 48; 435-442.
  28. Akimoto S, Okumara A, Fuse H: Relationship between serum levels of interleukina-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 1998; 45; 183-189.
  29. Chang Nan-Shan: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-b. Am J Physiol 1997; 273; 1987-1994.
  30. Muenchen HJ, Lin DL, Walson MA et al: Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappab by kappaâá-super repressor. Clin Cancer Res 2000; 6; 1969-1977.
  31. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103; 161-179.

correspondence

Anna Helmin-Basa
Zakład Immunologii Collegium Medicum
ul. Skłodowskiej-Curie 9
85-094 Bydgoszcz
tel. (052) 585 34 73
annahelmin@o2.pl